Study reveals one-third of mantle cell lymphoma patients in a study at leading cancer centers experienced disease progression ...

Friday, August 15, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Lowe's ...

Bristol Myers Squibb (BMS) has announced that its CD19-directed CAR T cell therapy Breyanzi (lisocabtagene maraleucel) has ...

Allogene Therapeutics Inc (ALLO) showcases significant progress in clinical trials and maintains a strong cash position, ...

Bristol Myers' Breyanzi sales surged 125% in Q2 to $344M, fueled by new approvals, strong demand and expanded market reach.

Bristol-Myers Squibb recently reported a strong earnings quarter. **The company raised its full-year revenue guidance by $700 million**. This update reflects robust sales growth from key therapies and ...

The FDA has accepted for priority review the sBLA for lisocabtagene maraleucel to treat relapsed/refractory MZL.

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Share price of Bristol Myers Squibb (BMY) touched a 52-week low of $42.96 on July 31, post its second-quarter earnings ...

Based on positive Phase II TRANSCEND FL data showing a 95.5% overall response rate, the FDA has accepted Bristol Myers Squibb’s sBLA for Breyanzi in relapsed or refractory MZL with a PDUFA date set ...